New research indicates that people who have achieved weight loss through injectable medications might be able to maintain their progress by switching to a daily oral pill. The study suggests this transition could offer a practical long-term strategy for managing weight, potentially providing a more convenient alternative to ongoing injections.
The findings, presented at the European Congress on Obesity, focused on individuals who had initially lost an average of 10.6% of their body weight using a weekly injectable treatment. After 68 weeks on the injectable, participants were then divided into groups, with one group transitioning to a daily pill containing semaglutide – the same active ingredient found in some popular weight loss injections. Another group received a placebo pill.
Over the subsequent 68 weeks, those who switched to the daily semaglutide pill maintained an impressive 89% of their initial weight loss. In contrast, participants who received the placebo pill regained 15% of their weight. This suggests the daily pill could be an effective tool in preventing weight regain after an initial period of more intensive treatment.
The daily pill, known as oral semaglutide, works by mimicking a hormone called GLP-1, which helps regulate appetite and food intake. This mechanism is similar to that of the injectable versions, but the oral formulation offers the potential for greater ease of use for some patients, removing the need for regular injections. This could improve adherence to treatment plans over extended periods.
While promising, the study highlights the need for continued medical supervision and a holistic approach to weight management, including diet and exercise, even when using medication. The availability of an oral option could broaden the accessibility of effective weight management tools for many individuals across the UK, potentially reducing the long-term health risks associated with obesity.
Further long-term studies are anticipated to fully understand the sustained efficacy and safety profile of this oral treatment in a wider population and to assess its integration into existing weight management pathways within the NHS and private healthcare sectors.